Virax Biolabs Group Ltd income statement VRAX
In fiscal 2025, which ended Mar 31, 2025, Virax Biolabs Group Ltd reported revenue of $6,331, down 96.0% from the year before. It recorded a net loss of $6.1 million. The operating loss came to $6.2 million, an operating margin of -97344.8%. Diluted earnings per share were -$1.62.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2025
Mar 31, 2025
|
FY 2024
Mar 31, 2024
|
FY 2023
Mar 31, 2023
|
FY 2022
Mar 31, 2022
|
|---|---|---|---|---|
| Revenue |
0
-96.0%
|
0
+1727.1%
|
0
|
0
|
| Cost of revenue |
0
-43.9%
|
0
+966.2%
|
0
-92.6%
|
—
|
| Gross profit |
-0
-204.9%
|
0
+3806.2%
|
-0
+85.5%
|
—
|
| Research and development |
2
+13.9%
|
2
-28.3%
|
2
+402.4%
|
0
|
| Selling, general and administrative |
4
-5.8%
|
5
+28.4%
|
4
+172.4%
|
1
|
| Operating expenses |
6
|
—
|
—
|
—
|
| Operating income |
-6
+5.1%
|
-6
-13.3%
|
-6
-230.7%
|
-2
|
| Pretax income |
-6
+7.9%
|
-7
-23.5%
|
-5
-211.9%
|
-2
|
| Income tax |
-0
|
—
|
—
|
—
|
| Net income |
-6
+10.0%
|
-7
-23.5%
|
-5
-211.9%
|
-2
|
| Basic EPS |
-1.62
+51.8%
|
-3.36
+34.5%
|
-5.13
|
—
|
| Diluted EPS |
-1.62
+51.8%
|
-3.36
+34.5%
|
-5.13
|
—
|
| Weighted average shares, basic |
4
+85.9%
|
2
+88.8%
|
1
+11.2%
|
1
|
| Weighted average shares, diluted |
4
+85.9%
|
2
+88.8%
|
1
+11.2%
|
1
|
| Other measures | ||||
| Depreciation and amortization |
0
+385.9%
|
0
|
—
|
—
|
| EBITDA |
-6
+8.5%
|
-6
|
—
|
—
|
| Margins | ||||
| Gross margin |
-838.21%
|
32.34%
|
-15.94%
|
—
|
| Operating margin |
-97,344.76%
|
-4,153.25%
|
-66,963.68%
|
—
|
| Pretax margin |
-97,992.31%
|
-4,308.38%
|
-63,751.47%
|
—
|
| Profit margin |
-95,833.71%
|
-4,308.38%
|
-63,751.47%
|
—
|
| EBITDA margin |
-93,133.72%
|
-4,118.17%
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VRAX (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Lanarkshire, United Kingdom
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885827
- Former names
- Virax Biolabs (Cayman) Ltd (until Dec 27, 2021)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.